# Peter Attia's blood tests: the full panel, the five that matter most, and where he goes past the guidelines

> ApoB, Lp(a), insulin and the rest of the Outlive list, with the mainstream guideline beside every one of his positions so you can see which parts are standard medicine and which are his own call.

*heart · The LifeFrom Team · November 19, 2026 · 11 min read*
Canonical: https://lifefrom.ai/blog/peter-attia-blood-tests

## The distinctions

- **His tests are mostly mainstream, his targets are his own.** A cardiologist following the 2018 AHA/ACC or 2019 ESC/EAS cholesterol guideline can already order apoB and hs-CRP, and European and US lipid societies advise testing Lp(a) once in every adult. Attia aims lower and starts earlier, and no trial has tested driving apoB that low from early adulthood in healthy people. The tests themselves are widely available; the targets are a conversation to have with your clinician.

---

Peter Attia, the physician behind the 2023 book Outlive, builds his blood work around five tests: apoB, a single Lp(a) test, fasting insulin, hs-CRP (an inflammation marker), and liver and kidney chemistry, with hormones and nutrients added after that. He reads the results for where a patient's arteries and metabolism are heading over the next 30 years. His list, often sold as a longevity blood panel or the Outlive blood tests, has spread across clinics, at-home kits and forums, often with exact targets that cite no book page or episode of his. Below, each test sits beside the guideline that already backs it, and the places where he goes further are marked.

**Key takeaways**
- Most of Attia's blood tests are guideline-backed. The AHA/ACC guideline counts apoB and hs-CRP as risk enhancers, the ESC/EAS guideline recommends apoB for risk assessment, and European and US lipid societies advise measuring Lp(a) once in every adult. His targets are his own: he wants apoB far lower, and earlier in life, than guidelines require.
- Lp(a) needs one test. Most other tests are worth repeating about once a year, and 4 to 12 weeks after a change in diet or medicine.
- HbA1c and fasting glucose can stay normal for years while insulin climbs, which is why he adds fasting insulin.
- The 'optimal' ranges for hormones, vitamin D and the omega-3 index are the least proven parts of his list.

## Peter Attia's blood tests, in one table

Attia organises prevention around what he calls the four horsemen: atherosclerotic heart disease, cancer, neurodegenerative disease such as Alzheimer's, and metabolic disease including [type 2 diabetes](/conditions/type-2-diabetes) [1]. His blood list maps onto them. The guideline column cites the American Heart Association and American College of Cardiology (AHA/ACC), the European cardiology and atherosclerosis societies (ESC/EAS), the American Diabetes Association (ADA) and the international kidney guideline group (KDIGO). A 'risk enhancer' is a result that tips a borderline heart-risk estimate toward treatment.

| Test | What it tells you | What Attia stresses | What guidelines say |
| --- | --- | --- | --- |
| ApoB | How many particles can lodge in artery walls | His first lipid number; lower for longer | Risk enhancer at 130 mg/dL or more (AHA/ACC); recommended for risk assessment (ESC/EAS) |
| Lp(a) | An inherited particle that adds heart and valve risk | Test everyone once | Measure once in every adult (ESC/EAS 2019, EAS 2022, NLA 2024); AHA/ACC mainly with a family history |
| Lipid panel (LDL-C, HDL-C, triglycerides) | The routine cholesterol read | Useful, ranked behind apoB | The base of every heart risk assessment |
| hs-CRP | Low-grade inflammation | Context for heart risk | Risk enhancer at 2.0 mg/L or more (AHA/ACC) |
| HbA1c and fasting glucose | Average and fasting blood sugar | Late signals; normal values can hide insulin resistance | Prediabetes 5.7 to 6.4%, diabetes 6.5% or more (ADA) |
| Fasting insulin, or an oral glucose tolerance test (OGTT) with insulin | How hard the pancreas works to keep glucose normal | An earlier warning than glucose | No agreed cutoff; not part of routine screening |
| Uric acid, triglyceride/HDL ratio | Side signals of metabolic strain | Read alongside insulin | Uric acid is checked mainly for gout and kidney stones |
| ALT, AST (liver enzymes), GGT | Liver cell stress, including fatty liver | Fatty liver can sit inside a 'normal' ALT | ALT and AST come in the standard metabolic panel; GGT is an add-on |
| Creatinine-based eGFR, cystatin C | How well the kidneys filter | Creatinine misreads muscular people | KDIGO 2024: add cystatin C when accuracy matters |
| Testosterone with SHBG (its binding protein), thyroid panel, DHEA-S | Hormone status | Tracked over time | Ordered when symptoms point to them |
| Vitamin D, ferritin, RBC magnesium, omega-3 index | Nutrient status | Tracked over time | Endocrine Society 2024 suggests against routine vitamin D testing in healthy adults |
| APOE genotype | Inherited Alzheimer's risk | Central to his brain-health chapter | No guideline recommends it as a population screen |

Exact Attia targets for TSH, ALT or fasting insulin that circulate online usually cite no book page or episode. The positions in this table come from Outlive [1], and every number is a guideline value you can check against its source.

## Who he is, and why people copy his panel

Attia is a physician (Stanford medical school, surgical training at Johns Hopkins) who runs a longevity practice, hosts the podcast The Drive and wrote Outlive: The Science and Art of Longevity with Bill Gifford, published by Harmony Books in March 2023 [1]. His frame is what he calls Medicine 3.0: act on risk decades before a disease can be diagnosed, instead of treating it once it arrives. That is why his panel goes deeper than a routine physical. The [longevity hub](/for/longevity) collects the wider topic.

## If you only get five: the short list

1. ApoB: the particle count behind heart disease, and Attia's first lipid number.
2. Lp(a), once: inherited, missing from a standard lipid panel, and close to fixed for life.
3. Fasting insulin beside fasting glucose and HbA1c: the early read on insulin resistance. An OGTT (a sugar drink with blood drawn over two hours) with insulin goes further.
4. hs-CRP (high-sensitivity C-reactive protein): a low-grade inflammation signal that the AHA/ACC guideline counts as a risk enhancer at 2.0 mg/L or more [2].
5. A comprehensive metabolic panel (CMP, the routine chemistry panel with liver and kidney tests) plus cystatin C.

A routine US physical usually includes the lipid panel and the CMP, and often HbA1c. ApoB, Lp(a), fasting insulin, hs-CRP and cystatin C are the ones you normally have to ask for by name. Our guide to [what blood tests to get](/learn/what-blood-tests-should-i-get) covers the wider list by age and sex.

## ApoB: the number he cares about most

Every particle that can push cholesterol into an artery wall (LDL and its close relatives VLDL, IDL and Lp(a)) carries exactly one apolipoprotein B molecule, so an apoB result is a particle count. LDL cholesterol measures how much cholesterol those particles carry. When the two disagree, risk tends to follow apoB. A 2022 UK Biobank analysis by Marston and colleagues found that heart attack risk tracked the number of apoB particles, whether they were LDL or triglyceride-rich particles [7]. The [apoB vs LDL comparison](/compare/apob-vs-ldl) works through when the two numbers part ways.

Attia's view, set out in Outlive, is that apoB damage builds up over a lifetime, so he wants apoB as low as can be reached safely and as early as possible [1]. He gives no single target for everyone. His reference point is the very low apoB of children, far below any adult guideline goal. Guidelines step in later and aim less low. The AHA/ACC 2018 guideline treats an apoB of 130 mg/dL or more as a risk-enhancing factor [2]. The ESC/EAS 2019 guideline recommends apoB for risk assessment, especially in people with high triglycerides, diabetes, obesity or very low LDL-C, and sets goals by risk level [3].

| Risk level (ESC/EAS 2019) | ApoB goal | LDL-C goal |
| --- | --- | --- |
| Very high | Below 65 mg/dL | Below 55 mg/dL and at least a 50% cut |
| High | Below 80 mg/dL | Below 70 mg/dL and at least a 50% cut |
| Moderate | Below 100 mg/dL | Below 100 mg/dL |

If your apoB is 130 mg/dL or more, or above the goal for your risk level, take it to a clinician with your family history and ask what your 10-year heart risk is and whether treatment makes sense. Lowering apoB usually starts with food (less saturated fat, more fibre) and, when a clinician judges it worthwhile, moves to medicines such as [statins](/compounds/statins), ezetimibe or PCSK9 inhibitors.

If apoB is missing from your report, [non-HDL cholesterol](/biomarkers/non-hdl-cholesterol) (total cholesterol minus HDL) is a free stand-in from the lipid panel you already have. The [cholesterol ratio calculator](/calculators/cholesterol-ratio) does the arithmetic, and [how to read your lipid panel](/learn/how-to-read-your-lipid-panel) covers the rest of the report.

> **An LDL of 190 or more goes to a clinician.** An LDL cholesterol of 190 mg/dL or more puts you in the group the AHA/ACC guideline treats as severe hypercholesterolemia, which is often inherited [2]. Show that number to a clinician instead of working on it alone, and read about [familial hypercholesterolemia](/conditions/familial-hypercholesterolemia). If your report shows only total cholesterol, the [LDL calculator](/calculators/ldl) estimates it.

## Lp(a): test it once, then plan around it

Lipoprotein(a), written Lp(a), is an LDL-like particle with an extra protein attached. The LPA gene sets most of its level, so diet and exercise barely move it, and about 1 in 5 people carry enough Lp(a) to raise heart attack and aortic valve risk [4]. Statins tend to nudge Lp(a) up slightly on average [8]. That small rise is no reason to stop a statin, because the apoB it lowers matters more. A standard lipid panel never reports Lp(a), so Attia argues that everyone should have it measured once [1], and the European guideline agrees.

> Lp(a) measurement should be considered at least once in each adult person's lifetime to identify those with very high inherited Lp(a) levels >180 mg/dL (>430 nmol/L) who may have a lifetime risk of ASCVD equivalent to the risk associated with heterozygous familial hypercholesterolaemia.
> (2019 ESC/EAS Guidelines for the management of dyslipidaemias [[3]])

In plain words, one Lp(a) test can find people whose inherited heart risk matches that of familial hypercholesterolemia, a genetic cholesterol disorder. The EAS 2022 consensus [4] and the National Lipid Association's 2024 update [9] also say to measure Lp(a) at least once in every adult. The US AHA/ACC guideline is narrower and suggests Lp(a) mainly for people with a family history of early heart disease [2].

Labs report Lp(a) in nmol/L, a particle count, or in mg/dL, a mass. No exact factor converts one to the other, so compare a result only against cutoffs in its own unit.

A high Lp(a) changes the plan around it. The EAS 2022 consensus advises treating other risk factors, apoB included, more intensively when Lp(a) is high, and testing first-degree relatives because the trait is inherited [4]. Drugs built to lower Lp(a) directly, such as pelacarsen and olpasiran, have gone into large outcome trials to see whether they prevent heart attacks and strokes. If yours is high, ask your clinician where those drugs stand and whether one, or a trial, suits you. For now, the main lever a clinician can use is lowering apoB.

## Metabolic health: why HbA1c is not enough for him

The ADA defines [prediabetes](/conditions/prediabetes) as an [HbA1c](/biomarkers/hba1c) of 5.7 to 6.4% and diabetes as 6.5% or more [5]. Attia's objection is timing. HbA1c and fasting glucose can stay normal for years while the pancreas pours out extra insulin to hold them there [1]. So he treats the ADA lines as late signals and measures insulin itself, either [fasting](/biomarkers/fasting-insulin) or across an OGTT with insulin drawn at each time point. He has also described wearing a continuous glucose monitor (CGM) to see how meals land [1]. Exact Attia HbA1c targets that circulate online, such as below 5.5%, usually come without a source.

> **A diabetes-range result goes to a clinician.** An HbA1c of 6.5% or more, or a fasting glucose of 126 mg/dL or more, is in the ADA's diabetes range [5]. Take it to a clinician rather than working on it alone. Very high glucose with heavy thirst, frequent urination or weight loss you cannot explain needs care the same day.

HOMA-IR turns a fasting insulin and a fasting glucose into one estimate of insulin resistance: insulin (µU/mL) times glucose (mg/dL), divided by 405 [10]. Insulin assays differ between labs and there is no universal HOMA-IR cutoff, so read it as a trend in your own numbers.

The triglyceride-to-HDL ratio and [uric acid](/biomarkers/uric-acid), which doctors usually check for [gout](/conditions/gout), are cheaper side signals of the same strain. The [two-hour OGTT glucose](/biomarkers/ogtt-2h-glucose) catches after-meal problems a fasting test misses. The [A1C vs fasting glucose comparison](/compare/a1c-vs-fasting-glucose) explains what each standard test leaves out, and [insulin resistance](/conditions/insulin-resistance) covers the condition itself.

## Inflammation, liver and kidneys

[hs-CRP](/biomarkers/hs-crp) reads low-grade inflammation in mg/L, and the AHA/ACC guideline counts 2.0 mg/L or more as a heart risk enhancer [2]. [hs-CRP vs CRP](/compare/hs-crp-vs-crp) explains why the two tests are read differently.

> **Retest a high hs-CRP once you are well.** A cold, a hard workout or a dental infection can raise hs-CRP for days, so one high reading is a reason to repeat the test after you recover. A result above 10 mg/L usually points to an active illness or injury. If it stays that high on the repeat, a clinician should look for the cause.

On the liver, Attia's concern is fatty liver hiding behind a 'normal' ALT [1]. Many labs set the ALT upper limit from populations that include people with undiagnosed fatty liver, so an ALT near the top of the range can still reflect fat in the liver. [GGT](/biomarkers/ggt) (gamma-glutamyl transferase) adds a read on alcohol and bile-duct stress, and the [AST/ALT ratio](/calculators/ast-alt-ratio) helps separate patterns. See [liver enzymes explained](/learn/liver-enzymes-explained) and [fatty liver](/conditions/fatty-liver).

For the kidneys, the usual eGFR (estimated glomerular filtration rate, how much blood the kidneys filter each minute) is calculated from creatinine, which comes from muscle. A muscular person can look as if their kidneys filter less than they do. The KDIGO 2024 kidney guideline supports adding [cystatin C](/biomarkers/cystatin-c), which muscle mass does not drive, when a more accurate eGFR matters [11]. [Cystatin C vs creatinine](/compare/cystatin-c-vs-creatinine) shows when the two disagree. [Homocysteine](/biomarkers/homocysteine) appears on many longevity panels too, and a high result often traces back to low B12 or folate.

## Hormones and nutrients: where the evidence is softest

Attia also tracks [testosterone](/biomarkers/testosterone-total) with SHBG (the binding protein that decides how much testosterone is free to act), a thyroid panel (TSH, free T4, free T3), DHEA-S (an adrenal hormone), vitamin D, ferritin, magnesium and the omega-3 index. These tests are worth knowing, and they are where copying someone else's target matters least. The ['optimal' ranges](/learn/reference-ranges-explained) that circulate for them come mostly from observational studies, where people with a given level did better, which leaves open whether the level caused the benefit.

| Test | What the 'optimal' range rests on | Where guidelines stand |
| --- | --- | --- |
| Vitamin D (25-OH D) | Observational links; the VITAL trial found no cancer or heart benefit from supplements | Endocrine Society 2024 suggests against routine testing in healthy adults and sets no target level |
| Omega-3 index | 8% or more linked with the lowest coronary death rates in observational data | No guideline target, and no trial has tested raising the index to 8% |
| RBC magnesium | Promoted by longevity clinics as a better read of body stores than serum magnesium | No guideline has adopted it |
| Ferritin | Low means thin iron stores; high can mean inflammation, liver disease or iron overload | Read with the rest of the iron tests; both ends matter |

> **Vitamin D pills did not prevent cancer or heart disease in VITAL.** In the VITAL trial of 25,871 US adults, vitamin D3 did not lower rates of invasive cancer or major cardiovascular events compared with placebo [12]. The Endocrine Society's 2024 guideline now suggests against routine vitamin D testing in generally healthy adults and does not set a target vitamin D level [6]. If yours has already been measured, the [vitamin D marker page](/biomarkers/vitamin-d-25-oh) explains the result and the [vitamin D](/compounds/vitamin-d) page covers when supplementing helps.

The omega-3 index measures EPA and DHA as a share of the fats in red cell membranes, and the 8% figure comes from observational data published in 2004 [13]. The [omega-3](/compounds/omega-3) page grades the fish oil trials, and [RBC magnesium](/biomarkers/magnesium-rbc) has its own page. A low [ferritin](/biomarkers/ferritin) is worth raising with a clinician, and a high one can point to [hemochromatosis](/conditions/hemochromatosis), an inherited iron overload.

For the hormone tests, start with the [male hormone panel guide](/learn/male-hormone-panel-explained), the [free testosterone calculator](/calculators/free-testosterone) and [how to read your thyroid panel](/learn/how-to-read-your-thyroid-panel).

## The tests that are not blood tests

Attia weighs several measures that need no blood draw as heavily as anything on the panel [1].

- VO2 max, the most oxygen your body can use during hard exercise. Attia treats cardiorespiratory fitness as one of the strongest predictors of how long people live [1]. The [VO2 max calculator](/calculators/vo2-max) gives an estimate without a lab.
- A DEXA scan, which measures muscle, visceral fat and bone density in one low-dose scan. Without a scan, the [lean body mass](/calculators/lean-body-mass) and [body fat](/calculators/body-fat) calculators give a rougher read.
- Coronary imaging. A [coronary calcium score](/learn/coronary-calcium-score) shows hardened plaque. Attia has written that he favours CT angiography for some patients because it also shows soft plaque that a calcium score of zero can miss [1].
- Cancer screening. He argues for starting colonoscopy earlier than 45, the age at which the US Preventive Services Task Force (USPSTF) starts routine colorectal screening [1] [14]. For [PSA](/biomarkers/psa-total), the USPSTF advises men aged 55 to 69 to decide individually and recommends against screening at 70 and older [15]. Multi-cancer blood tests are covered in [the Galleri test](/learn/galleri-test).

One genetic test sits on his list as well. APOE genotype shows inherited Alzheimer's risk and is central to his brain-health chapter [1], but no guideline recommends it as a screen. A result cannot be unlearned, and for people without memory symptoms no treatment depends on it (it matters mainly when someone with Alzheimer's is weighing an anti-amyloid drug, whose brain-swelling risk is higher in APOE4 carriers), so if you are curious, talk it through with a clinician or genetic counsellor first.

## How often to retest

A workable rhythm has four parts: one full baseline, Lp(a) once, most other tests about once a year, and a recheck 4 to 12 weeks after a change in diet or medicine to see whether it worked. The 4-to-12-week window matches the AHA/ACC guideline's advice for checking lipids after a statin is started or changed [2]. Repeat Lp(a) only if the first result was borderline or the lab's method was questionable.

The split follows biology. Genes set Lp(a), so one good measurement does the job. ApoB, insulin, hs-CRP and liver enzymes move with diet, weight and medicine, so the second and third readings tell you more than the first. Three readings from the same lab with the same preparation make a trend. Keep [fasting](/learn/fasting-before-a-blood-test) consistent, skip hard exercise the day before, and draw at a similar time of day. See [why trends beat single readings](/learn/trends-beat-single-readings), [how to prepare for a blood test](/learn/how-to-prepare-for-a-blood-test) and [exercise before a blood test](/learn/exercise-before-a-blood-test).

## How to get these tests in the US

A regular doctor can order every blood test on this list. If you want them, ask by name and tell your doctor about anything that applies to you, such as a family history of early heart disease, high triglycerides, an HbA1c in the prediabetes range, or a muscular build that skews creatinine. Insurance plans differ in what they cover for apoB, Lp(a) and cystatin C. Direct-to-consumer labs also sell most of these tests at cash prices.

To compare options, see [the cheapest blood tests](/compare/cheapest-blood-tests), [the best at-home blood tests](/compare/best-at-home-blood-tests) and [whether at-home tests are accurate](/learn/are-at-home-blood-tests-accurate). Whoop Advanced Labs is one consumer bundle built around many of these markers.

## Already have results? Read them line by line

If you already hold a lipid panel and a CMP, you have roughly half of the tests on Attia's list, and those results are worth reading closely before adding more. A high apoB or Lp(a) is a result to take to a clinician. It is no reason to start a supplement or a diet protocol on your own.

[Drop in your lab report and see every marker explained in plain words, placed on the body, against your lab's range. It's read on your device: nothing is uploaded and nothing is kept.](https://lifefrom.ai/read/blood-test)

## Common questions

**What are Peter Attia's top 5 blood tests?**

The five that do most of the work on his list are apoB, Lp(a) measured once, fasting insulin alongside fasting glucose and HbA1c, hs-CRP, and a comprehensive metabolic panel with cystatin C for the liver and kidneys. A routine US physical usually covers the lipid panel and metabolic panel. ApoB, Lp(a), fasting insulin, hs-CRP and cystatin C usually have to be requested.

**What apoB level does Peter Attia aim for?**

He does not publish one apoB target for everyone. In Outlive he argues for apoB as low as can be reached safely and as early in life as possible, with the very low levels seen in children as the reference point. Guidelines set firmer lines: the AHA/ACC 2018 guideline calls apoB of 130 mg/dL or more a risk enhancer, and the ESC/EAS 2019 guideline sets goals of below 100, 80 or 65 mg/dL for moderate, high and very high risk.

**What HbA1c does Peter Attia aim for?**

Exact figures that circulate online, such as below 5.5%, usually come without a book page or episode. What he sets out in Outlive is that the ADA lines, 5.7% for prediabetes and 6.5% for diabetes, are late signals, so he reads HbA1c alongside fasting insulin or an OGTT with insulin to catch insulin resistance years earlier.

**Does Peter Attia say everyone should test Lp(a)?**

Yes. He argues everyone should have Lp(a) measured once, and the 2019 ESC/EAS guideline, the 2022 EAS consensus and the National Lipid Association's 2024 update all recommend measuring it at least once in every adult. The US AHA/ACC guideline suggests it mainly when there is a family history of early heart disease. Because the LPA gene sets most of the level, one good measurement is usually enough.

**How often should you repeat an Attia-style blood panel?**

A workable rhythm is one full baseline, Lp(a) once, most other markers about once a year, and a recheck 4 to 12 weeks after changing diet or medicine to see the effect. Use the same lab and the same preparation each time so the numbers form a trend.

**Is Peter Attia's panel worth it if I'm healthy and 30?**

Mostly yes for the heart and metabolic tests, mostly no for the rest. ApoB and insulin resistance do their damage over decades and Lp(a) only needs one test, so those make the strongest case for testing young. The hormone and nutrient tests add the least for a healthy 30-year-old, since their 'optimal' targets rest mostly on observational data. Which tests are worth it for you is a question to settle with your own clinician.

## Sources

1. Attia P, Gifford B. Outlive: The Science and Art of Longevity. Harmony Books, 2023. <https://peterattiamd.com/outlive/>
2. Grundy SM et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. Circulation 2019;139:e1082-e1143. <https://www.ahajournals.org/doi/10.1161/CIR.0000000000000625>
3. Mach F et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal 2020;41(1):111-188. <https://academic.oup.com/eurheartj/article/41/1/111/5556353>
4. Kronenberg F et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. European Heart Journal 2022;43(39):3925-3946. <https://academic.oup.com/eurheartj/article/43/39/3925/6670882>
5. American Diabetes Association Professional Practice Committee. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes 2025. Diabetes Care 2025;48(Suppl 1):S27-S49. <https://diabetesjournals.org/care/article/48/Supplement_1/S27/157566>
6. Demay MB et al. Vitamin D for the Prevention of Disease: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism 2024;109(8):1907-1947. <https://academic.oup.com/jcem/article/109/8/1907/7685305>
7. Marston NA et al. Association of Apolipoprotein B-Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis. JAMA Cardiology 2022;7(3):250-256. <https://doi.org/10.1001/jamacardio.2021.5083>
8. Tsimikas S et al. Statin therapy increases lipoprotein(a) levels. European Heart Journal 2020;41(24):2275-2284. <https://doi.org/10.1093/eurheartj/ehz310>
9. Koschinsky ML et al. A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice. Journal of Clinical Lipidology 2024;18(3):e308-e319. <https://doi.org/10.1016/j.jacl.2024.03.001>
10. Matthews DR et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28(7):412-419. <https://doi.org/10.1007/BF00280883>
11. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney International 2024;105(4S):S117-S314. <https://doi.org/10.1016/j.kint.2023.10.018>
12. Manson JE et al. Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease (VITAL). New England Journal of Medicine 2019;380(1):33-44. <https://doi.org/10.1056/NEJMoa1809944>
13. Harris WS, von Schacky C. The Omega-3 Index: a new risk factor for death from coronary heart disease? Preventive Medicine 2004;39(1):212-220. <https://doi.org/10.1016/j.ypmed.2004.02.030>
14. US Preventive Services Task Force. Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement. JAMA 2021;325(19):1965-1977. <https://doi.org/10.1001/jama.2021.6238>
15. US Preventive Services Task Force. Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement. JAMA 2018;319(18):1901-1913. <https://doi.org/10.1001/jama.2018.3710>
